Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache SocietyGlobeNewsWire • 06/09/22
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences ConferenceGlobeNewsWire • 06/08/22
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/16/22
Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/16/22
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/12/22
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022GlobeNewsWire • 05/09/22
Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate TransformationGlobeNewsWire • 04/25/22
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare ConferenceGlobeNewsWire • 04/07/22
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/24/22
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/24/22
Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of NeurologyGlobeNewsWire • 03/22/22
Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022GlobeNewsWire • 03/17/22
Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With OaktreeGlobeNewsWire • 03/17/22
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business HighlightsGlobeNewsWire • 01/18/22
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/15/21
Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/15/21
Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of MigrainePRNewsWire • 09/29/21
Carepoint Pharmacy Selected by Impel NeuroPharma as a Digital Pharmacy Partner for the Launch of Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of MigrainePRNewsWire • 09/28/21
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of MigraineGlobeNewsWire • 09/28/21